Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.
Kenneth N OlivierDavid E GriffithGina EagleJohn P McGinnisLiza MicioniKeith LiuCharles L DaleyKevin L WinthropStephen RuossDoreen J Addrizzo-HarrisPatrick A FlumeDaniel DorganMatthias SalatheBarbara A Brown-ElliottRenu GuptaRichard J WallacePublished in: American journal of respiratory and critical care medicine (2017)
Although the primary endpoint was not reached, LAI added to a multidrug regimen produced improvements in sputum conversion and 6-minute-walk distance versus placebo with limited systemic toxicity in patients with refractory MAC lung disease. Further research in this area is needed. Clinical trial registered with www.clinicaltrials.gov (NCT01315236).